The estimated Net Worth of Ira Scott Greenspan is at least $1.25 Milión dollars as of 27 August 2021. Mr Greenspan owns over 900 units of Scopus Biopharma stock worth over $1 and over the last 8 years he sold SCPS stock worth over $1,070,639. In addition, he makes $180,000 as Sr. Advisor & Director at Scopus Biopharma.
Mr has made over 13 trades of the Scopus Biopharma stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 900 units of SCPS stock worth $4,473 on 27 August 2021.
The largest trade he's ever made was selling 532,255 units of Scopus Biopharma stock on 1 June 2018 worth over $516,287. On average, Mr trades about 62,122 units every 66 days since 2016. As of 27 August 2021 he still owns at least 14,640 units of Scopus Biopharma stock.
You can see the complete history of Mr Greenspan stock trades at the bottom of the page.
Ira Scott Greenspan is the Sr. Advisor & Director at Scopus Biopharma.
As the Sr. Advisor & Director of Scopus Biopharma, the total compensation of Mr Greenspan at Scopus Biopharma is $180,000. There are no executives at Scopus Biopharma getting paid more.
Mr Greenspan is 62, he's been the Sr. Advisor & Director of Scopus Biopharma since . There are 1 older and 3 younger executives at Scopus Biopharma. The oldest executive at Scopus Biopharma Inc. is David Silberg, 72, who is the Sr. Advisor.
Ira's mailing address filed with the SEC is C/O SCOPUS BIOPHARMA INC., 420 LEXINGTON AVENUE, SUITE 300, NEW YORK, NY, 10170.
Over the last 4 years, insiders at Scopus Biopharma have traded over $0 worth of Scopus Biopharma stock and bought 21,190 units worth $148,408 . The most active insiders traders include Ira Scott Greenspan, Joshua R Lamstein a Robert J Gibson. On average, Scopus Biopharma executives and independent directors trade stock every 12 days with the average trade being worth of $0. The most recent stock trade was executed by Ira Scott Greenspan on 27 August 2021, trading 900 units of SCPS stock currently worth $4,473.
Scopus BioPharma Inc., a biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. Its lead development programs are immuno-oncology gene therapy for the treatment of various cancers, which include CO-sTiRNA, a STAT3 inhibitor gene therapy that drives tumor cell growth and anti-tumor immune suppression; and MRI-1867, a cannabinoid-1 receptor inverse agonist and inhibitor of inducible nitric oxide synthase for the treatment of systemic sclerosis. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.
Scopus Biopharma executives and other stock owners filed with the SEC include: